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Many inner ear diseases are not adequately treated by systemic delivery of medication. The bloode
cochlear barrier limits the concentration and size of molecules that leave the circulation and access the
inner ear. This paper reviews the updated status of intratympanic steroid injections (ITS) for the
treatment of inner ear disease. ITS is a nonaggressive procedure in which high concentrations of
medication reach the cochlea and systemic side effects are minimized. In addition, this procedure is
effective for cochleovestibular symptoms caused by various inner ear diseases including noise-induced
hearing loss, idiopathic sudden sensorineural hearing loss, Ménière’s disease, and autoimmune
inner ear disease. Although the effect of ITS on noise-induced hearing loss is inconclusive, there is a
possibility that its indications could be extended, with a new horizon for pharmacological,
neurotrophin, gene, and cell-based therapy.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
The inner ear is unique for drug delivery [1]. Drug access is
limited by the bloodecochlear barrier, which is anatomically and
functionally similar to the bloodebrain barrier [2,3]. The small size
and relative inaccessibility of the cochlea in humans present
additional challenges in drug delivery to the inner ear [4]. The co-
chlea is surrounded by hard bone and is approximately 2 mm in
diameter at the entrance. In additional, the organ of Corti within
the cochlea is very sensitive to shear stress, mechanical and
chemical damage. Since the cochlea contains only about 80 mL of
ﬂuid, it is susceptible to very small changes in ﬂuid volume [4].
Therefore, a delicate approach is required to avoid damage from
drug delivery [1].
Therapeutic management of inner ear disease is undergoing a
paradigm shift [5]. Initial treatments for inner ear disease including
aminoglycosides for bilateral Ménière’s disease and steroids for
sudden sensorineural hearing loss (SSNHL) are delivered systemi-
cally. Systemic delivery of medication has various drawbacks, such
as variable access to the inner ear due to the bloodecochlea barrier
and potential systemic side effects. Side effects of systemiclogy, Buddhist Tzu Chi Gen-
alien, Taiwan. Tel.: þ886 3
).
ddhist Compassion Relief Tzu Chimedications are affected by a range of pharmacokinetic factors that
inﬂuence the concentration of the drug in the inner ear, such as
varying volume of distribution in the body, variability in the ability
of different medications to cross the bloodelabyrinth barrier, and
different routes of excretion [6]. Extensive experience with intra-
tympanic (IT) injection of gentamicin inMénière’s disease opened a
door to inner ear therapy [7]. Basic and clinical research on IT
administration of drugs for inner ear disease has increased signif-
icantly [8]. Oral steroids have been at the forefront for many inner
ear diseases [9,10]. However, glucocorticoid and mineralocorticoid
receptors in the inner ear were discovered recently. Steroids may
affect the electrolyte and ﬂuid balance of the inner ear, and the
endocochlear potential [11,12]. The primary concern in usage of
systemic steroids has been potential side effects [5], ranging from
minor to potentially life-threatening. Systemic steroid therapy has
been associated with hyperglycemia, hypertension, hypokalemia,
peptic ulcer, osteoporosis, immune suppression, adrenal suppres-
sion [13], and serious organ damage [5]. These side effects often
lead to a change in medication or a switch to a less efﬁcacious
alternative. The clinical drive for safe and effective medications for
inner ear disorders has resulted in the development of techniques
for local drug delivery [5,14]. Strategies in IT delivery of drugs into
the inner ear for local absorption include injection, perfusion,
hydrogel vehicles, nanoparticle carriers, and microcatheter sys-
tems. This review provides information on the current status of IT
therapy (Fig. 1).Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. (A) Large arrow shows the round window membrane from Lee et al and
Copyright 201x, Slideworld. Reprinted with permission. (B) Intratympanic steroid in-
jection procedure. Injections are performed using an ofﬁce microscope with the pa-
tient (left ear) lying down. A small needle (e.g., no. 22 spinal puncture needle) and
syringe are used and the needle (small arrow) is passed through the tympanic
membrane so that the needle tip is near the round windowmembrane. The arrowhead
indicates the malleus.
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2.1. IT steroids for noise-induced hearing loss
Noise-induced hearing loss (NIHL) is thought to be due to me-
chanical and metabolic damage [15,16]. Mechanical damage in-
cludes trauma to the stereocilia, reticular lamina, hair cell
membranes, and the organ of Corti [17e20]. In a guinea pig
experiment, damage occurred in the region 8.74e14.44 mm from
the apex [21]. Takemura et al speculated that focal damage in the
9e14 mm region was caused primarily by direct mechanical dam-
age to the cells of the organ of Corti, and secondarily by cell death in
border regions [21]. Previous studies revealed that NIHL might
involve hypoxia and formation of free radicals. Hypoxia in NIHL
may reduce blood ﬂow and ﬁnally lead to reduction in the hearing
threshold [22]. Ischemia may induce reactive oxygen species and
glutamate excitotoxicity, and activate the cell death pathway
[23,24]. In addition, NIHL induces excitotoxicity and the formation
of nitric oxide by converting free radicals to much more active and
destructive species [21]. Excitotoxicity is triggered by Ca2þ entry
leading to inﬂux of ions and water. The cascades triggered by Ca2þ
include activation of free radicals, protease, and endonuclease [25].The effectiveness of steroids in reducing NIHL is not conclusive
[1]. In guinea pigs, infusion of dexamethasone resulted in a dose-
dependent reduction in loss of outer hair cells, and attenuation of
the auditory brainstem response shift 7 days after noise exposure
[21]. A direct infusion of methylprednisolone into the cochlea for
7 days after exposure of guinea pigs to impulse noise reduced hair
cell loss, and promoted the recovery of temporary hearing shifts
[26], but not permanent hearing loss. These ﬁndings suggest that IT
steroids may be an alternative for patients with signiﬁcant side
effects from systemic therapy [1].
2.2. IT steroids for Ménière’s disease
Itoh and Sakata reported improvement in 80% of patients with
vertigo who received IT steroid injections [27]. In a randomized
case-controlled clinical trial, IT dexamethasone demonstrated a
statistically signiﬁcant difference in complete vertigo control for
Ménière’s disease compared with a placebo [28]. Boleas-Aguirre
et al showed that vertigo was signiﬁcantly improved with inter-
mittent IT steroids for as long as 2 years in 91% of patients [29]. In
addition, Ménière’s disease-associated symptoms can be treated
with IT steroids [30].
2.3. IT steroids for idiopathic SSNHL
Sudden hearing loss is characterized by abrupt loss of hearing,
which is typically unilateral [12]. Up to 65% of patients experience
spontaneous recovery [31], usually within 2 weeks after the hear-
ing loss. The chance of recovery decreases the longer the time be-
tween onset and ﬁrst treatment. Proposed treatments include
vasodilators, steroids, antiviral agents, hyperbaric oxygen, and
plasmapheresis [12]. Infusion of rheological agents (e.g., dextran
and pentoxifylline) is the standard treatment used in some coun-
tries [9,10]. Wilson et al reported that systemic steroids were
beneﬁcial in patients with moderate to severe hearing loss [32].
However, 30e50% of patients did not respond to high-dosage oral
or intravenous steroid therapy, and IT steroid injections were pro-
posed as rescue therapy for those refractory cases [33e36]. IT
dexamethasone injections improved hearing in 39% of patient with
a pure tone average (PTA) improvement of 12 dB, versus 10% and
10 dB in the control group [36]. Plaza and Herráiz demonstrated
that 55% of patients had improvement after IT steroid injections
with a mean PTA improvement of 33 dB, versus 0% and 12 dB,
respectively, in those patients who refused therapy [37]. In diabetic
patients, IT steroid injections signiﬁcantly improved hearing in 70%
of patients with a mean PTA improvement of 41 dB, versus 67% and
25 dB, respectively, in patients who received intravenous dexa-
methasone [38]. Therefore, some authors promote IT steroids as the
ﬁrst-line therapy for all idiopathic SSNHL [33e39].
2.4. IT steroids for autoimmune inner ear disease
Autoimmune inner ear disease results in hearing loss when
immune regulation is compromised [1,40]. The results of treatment
with high-dose systemic steroids and local IT steroid delivery are
not conclusive [41,42]. Swan et al proposed local drug delivery to
correct autoimmune inner ear disease [1]. Ryan et al suggested
treatment with high-dose prednisolone, with methotrexate added
for relapses [43].
3. Potential drawbacks of IT steroid injections
IT drug delivery for inner ear disorders alleviates some of the
problems associated with systemic drug delivery. In recent years, IT
steroid delivery has become routine for inner ear disease. However,
Table 1
Results obtained using intratympanic steroid injection for inner ear disease [8].
Disease Author(s), year Patients,
n
Improvement
(patient, %)
Improvement
(dB or %)
Sudden
sensorineural
hearing loss
Parnes et al 1999
[34]
13 46 62 dB
Ho et al 2004 [35] 15 53 28 dB
Fitzgerald et al 2007
[52]
21 67 26.6 dB
Battaglia et al 2008
[53]
120 70 31 dB
Ménière’s
disease
Ito and Sakata 1991
[27]
61 78 d
Silverstein et al
1998 [30]
17 NS NS
Garduño-Anaya
et al 2005 [28]
22 82 10%
dB ¼ decibels; NS ¼ not statistically signiﬁcant.
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example, anatomic barriers to absorption at the round window
membrane, loss of drug down to the Eustachian tube, and the
varying pharmacokinetic proﬁles of medications currently used for
IT delivery [5]. The round window membrane is the primary
transfer site for IT therapy. In one study, about one-third of tem-
poral bones (i.e., the roundwindowmembrane) were obstructed by
a pseudo membrane, ﬁbrous tissue, or a fat plug [44]. Loss of
medication via the Eustachian tube is another anatomic consider-
ation that may affect the efﬁcacy of IT steroid injection. Results of
animal studies suggest potential ototoxicity of direct steroid
application [45]. Persistent tympanic perforation, short-duration
vertigo, tinnitus, and otitis media were reported after perfusion of
high concentrations of steroids [46], but the incidencewas very low
in clinical applications.
4. The ﬁnite element method to predict drug concentrations
in the cochlea with IT injections
One contributing factor in the variation in drug delivery is the
absence of reliable data on the pharmacokinetics of drugs delivered
into the inner ear [47]. In humans, direct measurements of time-
dependent alterations of drug concentrations in the inner ear are
almost impossible. Therefore, computer simulation is a valuable
tool for estimating drug concentrations in the inner ear [48]. Sim-
ulations have been used to interpret published data on gentamicin
and corticosteroid perilymph concentrations in the chinchilla and
guinea pig cochlea [49,50]. An established one-dimensional simu-
lation model (Washington University Cochlear Fluid Simulator,
FluidSim http://oto.wustl.edu/cochlea/model.htm [48]) has pro-
vided a good presentation of the longitudinal distribution of drugs.
Plontke et al developed a more advanced three-dimensional
simulation model to assist in both drug and drug delivery system
design [47]. This method can assist in understanding the existence
of substantial drug gradients across the scalae in the basal turn of
the cochlea. In addition, the development of a rationale-based local
drug delivery system to the inner ear and its successful establish-
ment in clinical practice can be accelerated [47].
5. Conclusion and future directions
IT drug delivery for the treatment of inner ear disease can
maximize drug concentrations in the cochlea and minimize sys-
temic dissemination. This method is relatively safe with minimal
risks. There are manymethods that can deliver drugs to the cochlea
using the route of the middle ear including passive and active drug
delivery systems [1]. Passive methods include biodegradable
polymers, hydrogel-based systems, and nanoparticles. Active
methods use a variety of components and devices including
microcatheters, microwicks, and osmotic pumps. Future perspec-
tives may extend the indications for IT steroid injections and offer a
new horizon for pharmacological, neurotrophin, gene, and cell-
based therapy. Patients with inner ear disease can look forward
to improvement in quality of life and relief of cochlea-vestibular
symptoms as the development of IT delivery progresses.
Hu and Parens conducted a literature review of some clinical
trials investigating IT steroid therapy for inner ear disorders [51].
They found that there are no good studies on IT steroid that meet
the criteria of comparability, internal validity, and external validity.
First, the data are heterogenous with respect to steroid doses,
treatment protocols, previous treatments, and deﬁnitions of dis-
ease and improvement. Second, Ménière’s disease and SSNHL have
a natural history of spontaneous resolution. Third, there is a lack of
placebo controls in many studies. Fourth, the sample sizes for the
studies are small. In the future, studies should be randomized andcontrolled to eliminate selection bias and the placebo effect. The
application of IT steroid injection for treatment of inner ear disease
is shown in Table 1 [8].
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